Adjuvant denosumab for early breast cancer–Evidence and controversy

Laura Moretti; Laura Richelmi; Deborah Cosentini; Rebecca Pedersini; Salvatore Grisanti; Vito Amoroso; Alfredo Berruti; Marta Laganà

Breast (Dec 2024)

Adjuvant denosumab for early breast cancer–Evidence and controversy

Laura Moretti,
Laura Richelmi,
Deborah Cosentini,
Rebecca Pedersini,
Salvatore Grisanti,
Vito Amoroso,
Alfredo Berruti,
Marta Laganà

Affiliations

Laura Moretti: Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy
Laura Richelmi: Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy
Deborah Cosentini: Corresponding author. Piazzale Spedali Civili, 1, 25123, BRESCIA, Italy.; Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy
Rebecca Pedersini: Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy
Salvatore Grisanti: Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy
Vito Amoroso: Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy
Alfredo Berruti: Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy
Marta Laganà: Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy

Journal volume & issue: Vol. 78
p. 103826

Abstract

Read online

The efficacy of adjuvant denosumab in combination with hormonotherapy in breast cancer patients was investigated in two randomized trials, ABCSG-18 and D-Care, but the results were mixed with respect to the impact of this drug on disease-free survival. However, the ABCSG-18 study has achieved its primary goal: prevention of clinical fractures. Therefore, the protective role of Denosumab on bone fragility induced by estrogen deprivation, already demonstrated in post-menopausal women, has been validated in the breast cancer setting.

Published in Breast

ISSN: 1532-3080 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/the-breast

About the journal